Creating new types of nanoparticles that act like monoclonal antibodies for cancer treatment
Official title: Nucleic Acid Nanoparticle-based Monoclonal Antibody Mimics
Funded at Ball State University · NIH-10201231 · Data updated 2026-11-12
This study is exploring new tiny particles made from genetic material that can work like antibodies to target prostate cancer cells, aiming to provide patients with better and more affordable treatment options.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ball State University NIH-funded |
| Lab location | 1 site (Muncie, United States) |
| Project start | September 1, 2021 |
| Project end | August 31, 2025 |
| Funding year | 2021 |
| Award (this year) | $417,416 |
| NIH project number | 1R15EB031388-01 |
| Project ID | NIH-10201231 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with prostate cancer who are seeking new treatment options.
✕Less likely to help
Patients with cancers other than prostate cancer may not receive direct benefits from this research.
What this research studies
This research focuses on developing innovative nucleic acid-based nanoparticles that mimic the function of monoclonal antibodies, which are commonly used in cancer treatment. By utilizing specially designed nucleic acid aptamers, the project aims to create nanoparticles that can bind specifically to prostate cancer cells, offering a potentially more stable and cost-effective alternative to traditional monoclonal antibodies. The approach involves engineering these nanoparticles to replicate the structural characteristics of various antibody types, enhancing their effectiveness in targeting cancer cells. Patients may benefit from improved treatment options that are less complex and more affordable.
Why it matters
Potential benefit: If successful, this research could lead to more effective and accessible cancer treatments with fewer side effects.
How similar studies have gone: Other research has shown promise in using nucleic acid aptamers as alternatives to monoclonal antibodies, indicating a potential for success in this novel approach.
Where this research is happening
-
Ball State University
Muncie, United States Active
Researchers
- Principal investigator: Khisamutdinov, Emil — Ball State University
- Study coordinator: Khisamutdinov, Emil
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.